Recon: Eli Lilly’s Omvoh bests J&J’s Stelara in late-stage study for Crohn’s; Innovation in the EU medtech market
ReconJason Scott
Biologics/ biosimilars/ vaccinesDigital health/SaMD/AIGlobalMedical DevicesPharmaceuticalsRegulatory Intelligence/Policy